PT - JOURNAL ARTICLE AU - Harald S. Vöhringer AU - Theo Sanderson AU - Matthew Sinnott AU - Nicola De Maio AU - Thuy Nguyen AU - Richard Goater AU - Frank Schwach AU - Ian Harrison AU - Joel Hellewell AU - Cristina Ariani AU - Sonia Gonçalves AU - David Jackson AU - Ian Johnston AU - Alexander W. Jung AU - Callum Saint AU - John Sillitoe AU - Maria Suciu AU - Nick Goldman AU - The Wellcome Sanger Institute Covid-19 Surveillance Team AU - The COVID-19 Genomics UK (COG-UK) Consortium AU - Ewan Birney AU - Sebastian Funk AU - Erik Volz AU - Dominic Kwiatkowski AU - Meera Chand AU - Inigo Martincorena AU - Jeffrey C. Barrett AU - Moritz Gerstung TI - Genomic reconstruction of the SARS-CoV-2 epidemic across England from September 2020 to May 2021 AID - 10.1101/2021.05.22.21257633 DP - 2021 Jan 01 TA - medRxiv PG - 2021.05.22.21257633 4099 - http://medrxiv.org/content/early/2021/05/26/2021.05.22.21257633.1.short 4100 - http://medrxiv.org/content/early/2021/05/26/2021.05.22.21257633.1.full AB - Despite regional successes in controlling the SARS-CoV-2 pandemic, global cases have reached an all time high in April 2021 in part due to the evolution of more transmissible variants. Here we use the dense genomic surveillance generated by the COVID-19 Genomics UK Consortium to reconstruct the dynamics of 62 different lineages in each of 315 English local authorities between September 2020 and April 2021. This analysis reveals a series of sub-epidemics that peaked in the early autumn of 2020, followed by a singular jump in transmissibility of the B.1.1.7 lineage. B.1.1.7 grew when other lineages declined during the second national lockdown and regionally tiered restrictions between November and December 2020. A third more stringent national lockdown eventually suppressed B.1.1.7 and eliminated nearly all other lineages in early 2021. However, a series of variants (mostly containing the spike E484K mutation) defied these trends and persisted at moderately increasing proportions. Accounting for sustained introductions, however, indicates that their transmissibility is unlikely to exceed that of B.1.1.7. Finally, B.1.617.2 was repeatedly introduced to England and grew rapidly in April 2021, constituting approximately 40% of sampled COVID-19 genomes on May 15.Competing Interest StatementThe authors have declared no competing interest.Funding StatementCOG-UK is supported by funding from the Medical Research Council (MRC) part of UK Research & Innovation (UKRI), the National Institute of Health Research (NIHR) and Genome Research Limited, operating as the Wellcome Sanger Institute. We would like to thank our colleagues at EMBL-EBI, the Wellcome Sanger Institute and from COG-UK for stimulating discussions and helpful comments on this manuscript. HSV and MG are supported by a grant from the Department of Health and Social Care. AWJ, EB and MG are beneficiaries from grant NNF17OC0027594 from the Novo Nordisk Foundation. TS is supported by grant 210918/Z/18/Z, and JH and SF by grant 210758/Z/18/Z from the Wellcome Trust. HSV, NDM, AWJ, NG, EB and MG are supported by EMBL.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was done as part of surveillance for COVID-19 under the auspices of Section 251 of the National Health Service Act 2006. It therefore did not require individual patient consent or ethical approval. The COVID-19 Genomics UK (COG-UK) study protocol was approved by the Public Health England Research Ethics Governance Group.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesPCR test data are publicly available at https://coronavirus.data.gov.uk/. SARS-CoV-2 genome data and geolocations can be obtained under controlled access from https://www.cogconsortium.uk/data/. A filtered, privacy conserving version of the data set is publicly available at https://covid19.sanger.ac.uk/downloads. The data and a version of the analysis with fewer lineages can be interactively explored at https://covid19.sanger.ac.uk. https://coronavirus.data.gov.uk/ https://www.cogconsortium.uk/data/ https://covid19.sanger.ac.uk/downloads https://covid19.sanger.ac.uk